Orchestra BioMed Prices 15M-Share Offering at $5.00
OBIO sits 45% above its 52-week low of $3.46.
Summary
Orchestra BioMed priced its underwritten public offering at $5.00 a share for 15 million shares, roughly $75 million in gross proceeds before fees, and underwriters hold an option to buy an additional 2.25 million shares. The company expects the offering to close Nov. 9. That follows the launch disclosed after Thursday's close, when the company announced the deal with no size or price. The price matches the last quoted $5.00, so there is no discount to the prior close, but 15 million new shares is a large increase in the share count for a company this size and dilutes existing holders meaningfully. Proceeds are earmarked for the BACKBEAT and Virtue programs, as well as research and clinical development of other product candidates, with the remainder for working capital and other general purposes; the financing matters because Q2 revenue was just $88K against a $23.8M net loss and the company has been leaning on financing to fund the pivotal trial work. The BACKBEAT pivotal data readout is the next hard event for the stock.
At the time of this announcement, OBIO was trading at $5.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $337.8M. The 52-week trading range was $3.46 to $6.50. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.